128 related articles for article (PubMed ID: 38845389)
1. Correction to "Physiologically-based pharmacokinetic pharmacodynamic parent-metabolite model of edoxaban to predict drug-drug-disease interactions: M4 contribution".
CPT Pharmacometrics Syst Pharmacol; 2024 Jun; ():. PubMed ID: 38845389
[No Abstract] [Full Text] [Related]
2. Physiologically-based pharmacokinetic pharmacodynamic parent-metabolite model of edoxaban to predict drug-drug-disease interactions: M4 contribution.
Xu R; Liu W; Ge W; He H; Jiang Q
CPT Pharmacometrics Syst Pharmacol; 2023 Aug; 12(8):1093-1106. PubMed ID: 37101392
[TBL] [Abstract][Full Text] [Related]
3. The edoxaban-M4 metabolite and measurement of edoxaban by chromogenic assays in human plasma.
Siriez R; Yildiz H; Bouvy C; Haguet H; Maloteau V; Hardy M; Mullier F; Dogné JM; Hainaut P; Douxfils J
Res Pract Thromb Haemost; 2022 Mar; 6(3):e12680. PubMed ID: 35434470
[TBL] [Abstract][Full Text] [Related]
4. Importance of measuring pharmacologically active metabolites of edoxaban: development and validation of an ultra-high-performance liquid chromatography coupled with a tandem mass spectrometry method.
Siriez R; Alpan L; Elasaad K; Devel P; Laloy J; Dogné JM; Douxfils J
J Thromb Thrombolysis; 2020 Apr; 49(3):395-403. PubMed ID: 31925664
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics of edoxaban and its main metabolite in a dedicated renal impairment study.
Jönsson S; Simonsson US; Miller R; Karlsson MO
J Clin Pharmacol; 2015 Nov; 55(11):1268-79. PubMed ID: 25966665
[TBL] [Abstract][Full Text] [Related]
6. Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporine.
Parasrampuria DA; Mendell J; Shi M; Matsushima N; Zahir H; Truitt K
Br J Clin Pharmacol; 2016 Dec; 82(6):1591-1600. PubMed ID: 27530188
[TBL] [Abstract][Full Text] [Related]
7. Edoxaban administration following enoxaparin: a pharmacodynamic, pharmacokinetic, and tolerability assessment in human subjects.
Zahir H; Matsushima N; Halim AB; He L; Zhang G; Lee F; Worland V; Mendell J
Thromb Haemost; 2012 Jul; 108(1):166-75. PubMed ID: 22628060
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous Ivabradine Parent-Metabolite PBPK/PD Modelling Using a Bayesian Estimation Method.
Lang J; Vincent L; Chenel M; Ogungbenro K; Galetin A
AAPS J; 2020 Oct; 22(6):129. PubMed ID: 33033962
[TBL] [Abstract][Full Text] [Related]
9. The effect of rifampin on the pharmacokinetics of edoxaban in healthy adults.
Mendell J; Chen S; He L; Desai M; Parasramupria DA
Clin Drug Investig; 2015 Jul; 35(7):447-53. PubMed ID: 26068927
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of anticoagulant edoxaban in overdose in a Japanese patient transported to hospital.
Adachi K; Tuchiya J; Beppu S; Nishiyama K; Shimizu M; Yamazaki H
J Pharm Health Care Sci; 2020; 6():20. PubMed ID: 32944263
[TBL] [Abstract][Full Text] [Related]
11. A Physiologically Based Pharmacokinetic and Pharmacodynamic Model of the CYP3A4 Substrate Felodipine for Drug-Drug Interaction Modeling.
Fuhr LM; Marok FZ; Mees M; Mahfoud F; Selzer D; Lehr T
Pharmaceutics; 2022 Jul; 14(7):. PubMed ID: 35890369
[TBL] [Abstract][Full Text] [Related]
12. Virtual Clinical Trial Toward Polytherapy Safety Assessment: Combination of Physiologically Based Pharmacokinetic/Pharmacodynamic-Based Modeling and Simulation Approach With Drug-Drug Interactions Involving Terfenadine as an Example.
Wiśniowska B; Polak S
J Pharm Sci; 2016 Nov; 105(11):3415-3424. PubMed ID: 27640752
[TBL] [Abstract][Full Text] [Related]
13. An integrated pharmacokinetic/pharmacogenomic analysis of ABCB1 and SLCO1B1 polymorphisms on edoxaban exposure.
Vandell AG; Lee J; Shi M; Rubets I; Brown KS; Walker JR
Pharmacogenomics J; 2018 Jan; 18(1):153-159. PubMed ID: 27897269
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the Drug-Drug Interaction Potential of Acalabrutinib and Its Active Metabolite, ACP-5862, Using a Physiologically-Based Pharmacokinetic Modeling Approach.
Zhou D; Podoll T; Xu Y; Moorthy G; Vishwanathan K; Ware J; Slatter JG; Al-Huniti N
CPT Pharmacometrics Syst Pharmacol; 2019 Jul; 8(7):489-499. PubMed ID: 31044521
[TBL] [Abstract][Full Text] [Related]
15. Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 Trial.
Yin OQP; Antman EM; Braunwald E; Mercuri MF; Miller R; Morrow D; Ruff CT; Truitt K; Weitz JI; Giugliano RP
Circulation; 2018 Oct; 138(18):1963-1973. PubMed ID: 29967197
[TBL] [Abstract][Full Text] [Related]
16. Impact of Hepatic CYP3A4 Ontogeny Functions on Drug-Drug Interaction Risk in Pediatric Physiologically-Based Pharmacokinetic/Pharmacodynamic Modeling: Critical Literature Review and Ivabradine Case Study.
Lang J; Vincent L; Chenel M; Ogungbenro K; Galetin A
Clin Pharmacol Ther; 2021 Jun; 109(6):1618-1630. PubMed ID: 33283268
[TBL] [Abstract][Full Text] [Related]
17. Ciprofol is primarily glucuronidated by UGT1A9 and predicted not to cause drug-drug interactions with typical substrates of CYP1A2, CYP2B6, and CYP2C19.
Hou L; Zhao Y; Zhao S; Zhang X; Yao X; Yang J; Wang Z; Chan ECY; Liu S
Chem Biol Interact; 2024 Jan; 387():110811. PubMed ID: 37993078
[TBL] [Abstract][Full Text] [Related]
18. Accelerating Clinical Development of Idasanutlin through a Physiologically Based Pharmacokinetic Modeling Risk Assessment for CYP450 Isoenzyme-Related Drug-Drug Interactions.
Umehara K; Cleary Y; Fowler S; Parrott N; Tuerck D
Drug Metab Dispos; 2022 Mar; 50(3):214-223. PubMed ID: 34937801
[TBL] [Abstract][Full Text] [Related]
19. Predicting the Effects of CYP2C19 and Carboxylesterases on Vicagrel, a Novel P2Y12 Antagonist, by Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling Approach.
Liu S; Wang Z; Tian X; Cai W
Front Pharmacol; 2020; 11():591854. PubMed ID: 33424602
[TBL] [Abstract][Full Text] [Related]
20. Physiologically based pharmacokinetic modeling to predict complex drug-drug interactions: a case study of AZD2327 and its metabolite, competitive and time-dependent CYP3A inhibitors.
Guo J; Zhou D; Li Y; Khanh BH
Biopharm Drug Dispos; 2015 Nov; 36(8):507-19. PubMed ID: 26081137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
